Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | EPOR | P19235 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL11558166 | 0.93 | EPHX2 (0.44) | SMN1; SMN2HTTRAB9ATSHRSPHK1 | |
| SCHEMBL11505841 | 0.90 | SMN1; SMN2 (0.55) | SMN1; SMN2HTTRAB9ATSHRSPHK1 | |
| SCHEMBL24487091 | 0.86 | RAB9A (0.50) | SMN1; SMN2RAB9ATSHRLMNAEPHX2 | |
| SCHEMBL12012359 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2HTTRAB9ATSHRLMNA | |
| SCHEMBL8114563 | 0.84 | EPHX2 (0.44) | SMN1; SMN2HTTRAB9ATSHRSPHK1 | |
| SCHEMBL5670789 | 0.83 | EPHX2 (0.40) | SMN1; SMN2SPHK1EPHX2 | |
| Sulfuric Acid SCHEMBL11563680 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2HTTTSHRSPHK1LMNA | |
| Hydrochloric Acid SCHEMBL3532520 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2HTTRAB9ATSHRSPHK1 | |
| SCHEMBL5391087 | 0.82 | TDP1 (0.49) | SMN1; SMN2TDP1L3MBTL1KDM4EPOLB | |
| SCHEMBL21533746 | 0.81 | HTT (0.49) | SMN1; SMN2HTTTSHRLMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015724-A | Thienopyrimidines | MERCK PATENT GMBH | 2011-04-13 | — | — | CN | disclosed |
| US-20110028472-A1 | THIENOPYRIMIDINES | MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-03 | — | — | US | disclosed |
| EP-2260044-A2 | THIENOPYRIMIDINES | Merck Patent GmbH (DE) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009124653-A2 | THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028472-A1 | THIENOPYRIMIDINES | TGFBR1, TYMP, TGFBR2 | SMN1; SMN2 3514/4885HTT 4492/4885RAB9A 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.